ĀÜĄņĀŅĀ×

Prof. Dr. Dr. med Thomas Thum is since 2009 the Director of the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hannover Medical School (MHH), since 2013 visiting Professor at the National Heart and Lung Institute at Imperial College London and since 2021 Director of the neighboring Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) in Hannover, Germany.

Thomas is a key opinion leader in heart failure and the development of RNA-based therapeutic strategies in cardiovascular medicine. He authored of over 400 scientific publications, appearing in leading journals e.g. Nature or Lancet.

Thomas is also a member of the editorial boards of the worldā€™s most prestigious journals for cardiovascular research. Furthermore, Thomas is a nucleus member of national and international research committees in the cardiovascular field, such as the European Society of Cardiology (ESC), the American Heart Association (AHA), and the International Society for Heart Research (ISHR). Thomas has received numerous awards for his work on non-coding RNAs in cardiovascular research. Thomas has filed over 40 patents, nine of which have been successfully licensed to pharma companies and are currently at phase I/II clinical development. Thomas is founder and CSO of Cardior.